Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib ; volume:21 ; number:1 ; day:23 ; month:6 ; year:2022 ; pages:1-4 ; date:12.2022
Molecular cancer ; 21, Heft 1 (23.6.2022), 1-4, 12.2022
- Urheber
-
Li, Ke-xin
Wu, Hui-yang
Pan, Wan-ying
Guo, Meng-qi
Qiu, De-zhi
He, Yan-jie
Li, Yu-hua
Yang, Dong-Hua
Huang, Yu-xian
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-022-01566-0
- URN
-
urn:nbn:de:101:1-2022081519521477423716
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Li, Ke-xin
- Wu, Hui-yang
- Pan, Wan-ying
- Guo, Meng-qi
- Qiu, De-zhi
- He, Yan-jie
- Li, Yu-hua
- Yang, Dong-Hua
- Huang, Yu-xian
- SpringerLink (Online service)
Ähnliche Objekte (12)
A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Management of relapsed-refractory diffuse large B cell lymphoma
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Update on the management of relapsed/refractory chronic lymphocytic leukemia
A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Management of relapsed-refractory diffuse large B cell lymphoma
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Update on the management of relapsed/refractory chronic lymphocytic leukemia
A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Management of relapsed-refractory diffuse large B cell lymphoma
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma